

GLYCOBOOST

European
Innovation
Council



Transition 2024

k
b
kyron.bio



GENOS

Maja Pučić Baković
GENOS d.o.o.
EIC INFO DAN
20. veljače 2025.



Dr. Emilia McLaughlin

Founder & CEO

EU Woman in leadership 2024

Pioneering Tomorrow's Therapeutics

through glycoengineering



IP protection:



Maintenance of 3 existing patent families



File 2 additional patent families

Appleyard Lees world-renowned antibody IP experts




Prof. Gordan Lauc

Founder & CEO

SEE THE COMPLETE
PICTURE **INCLUDE
GLYCANS IN YOUR
STUDY**

*Large scale glycan studies powered
by Genos, leading provider of
high throughput glycomics*



IP protection:

15+ years of
know-how, patents
& trade secrets



Built thanks to EU
funding

Eligible project: H2020 SYSCID


PROBLEM

Unwanted immune response

induced by

40% of autoimmune disease biologics

63% of oncology biologics



“


Solving the problem of non-response would be a *game-changer* for clinicians & patients ”

Prof. Michael Weinblatt
Harvard Professor & Clinician
Advisor to kyron.bio

OPPORTUNITY

Precision-controlled glycosylation

to make therapeutics safer and more effective for patients




k
b

Engineering for massively improved therapeutics


 **GENOS**

State-of-the-art
precision
glycoanalytics

GLYCOBOOST IMPLEMENTATION



Budget distribution





GO-TO-MARKET STRATEGY & FINANCIAL ROADMAP



MARKET OPPORTUNITY



COMPETITION

PROJECT TEAM & EXPERTISE

1st glycosylation precision control company & N°1 research organisation in Croatia




Dr. Emilia McLaughlin

Founder & CEO, kyron.bio

PhD Institut Pasteur Paris

EIC Woman in leadership 2024



Dr. Marina Lochhead

R&D Lead, kyron.bio

PhD Queen's University Canada

Postdoc Institut Curie Paris




Dr. Maja Pučić Baković

Vice-Lead Research Laboratory, Genos

PhD University of Zagreb

PI for HE project WORMVACS2.0



Dr. Tamara Štambuk

Lead Researcher, Genos

PhD University of Zagreb

PI for HE project INITIALISE

Advisory Board



Prof. Sir Michael Ferguson

Glycosylation expert
Head of Drug Discovery



Marie Moores

COO of BioInvent



Dr. Michael Weinblatt

Former President of American
College of Rheumatology



Dr. René Labatut

Former VP - Innovation
& Technology



Bjørn Voldborg

Head of National
Biologics Facility



Dr. Peter Pack

Serial entrepreneur



Dr. Gordan Lauc

CEO of Genos
CSO GlycanAge




OPPORTUNITY FOR EUROPE TO LEAD IN GLYCOBIOLOGY

1 Massive clinical unmet need
 > 40% non-response to antibodies for autoimmune diseases, oncology, etc.

2 Synergistic partnership
 Award-winning female-led glycobiology startup
 [World-class ERC-funded glycobiology research actor

3 Breakthrough innovation
 Powered by 4 high-potential female scientific leaders



PROPOSAL PREPARATION

General strategy:

- **Start with the end in mind!**
- **Equal quality** of Excellence, Impact & Implementation sections
- **Cross-referencing** while answering similar questions
- Provide **external validation** of your claims
- **Your proposal is your contract – careful what you commit to!**



PROPOSAL PREPARATION

1. EXCELLENCE

- Description of eligible **background project**
- **Technological breakthrough** (competitive advantages & commercial potential)
- **Technology and business objectives** (specific, measurable, achievable, relevant & time bound)
- **Methodology** (proposed approach, suitable and timely)



PROPOSAL PREPARATION

1. EXCELLENCE

2. IMPACT

- **Credibility of the impacts** (how activities support development, commercialisation, IP, etc.)
- **Economic and/or societal benefits** (health of EU citizens, increased productivity & competitiveness, employment opportunities, women in STEM, etc.)
- **Investment readiness** (go-to-market strategy, time-to-market, revenue model, etc.)




PROPOSAL PREPARATION

1. EXCELLENCE

2. IMPACT

3. IMPLEMENTATION

- Make sure **all figures are aligned!**
- Showcase **high-quality expertise, capabilities and motivation** of the team
- The **level of detail** should be comprehensive but not overwhelming (50% of jurists are NOT scientists)
- Equal distribution of responsibility
- EIC program targets „high-risk SMEs” but **fine balance** needs to be struck



INTERVIEW PREPARATION

Evaluation Result

Status: GO

Step-2 Jury Score

Status: GO

C.D.



THANK EU GLYCOBOOST

European
Innovation
Council



Transition 2024

